Oxford BioMedica PLC on Monday said it has expanded its licence and supply deal with Cabaletta Bio Inc.

Oxford Bio is an Oxfordshire, England-based gene and cell therapy group, while Cabaletta is a Philadelphia, Pennsylvania-based clinical-stage biotechnology company focused on curative cell therapies for autoimmune diseases.

Oxford Bio said its agreement with Cabaletta has been expanded to grant a non-exclusive licence to Cabaletta under Oxford Bio’s LentiVector platform IP for their CAR-T programme, CABA-201.

Oxford Bio initially licensed the LentiVector platform to Cabaletta for its lead candidate DSG3-CAART.

The company said Cabaletta has received two IND clearances for CABA-201, and is intending to launch a phase 1/2 clinical trial for patients with systemic lupus erythematosus and lupus nephritis immune diseases, as well as a separate trial for myositis.

Oxford Bio said it will receive an undisclosed upfront payment, as well as other payments relating to the development and manufacture of lentiviral vectors to be used in clinical trials. The company added that it will receive a milestone payment and a royalty on the sale of products using its platform.

Chief Executive Frank Mathias said: ‘The expansion of our partnership with Cabaletta Bio stands as a testament to Oxford Biomedica’s unwavering commitment to quality and innovation. As a world-leading [contract development & manufacturing organization] with expertise across all key viral vector types, we are committed to enabling our biopharma customers to discover and deliver transformative therapies.

‘We’re excited to continue our work with Cabaletta and help them deliver accessible cures for patients with severe autoimmune disease.’

Oxford BioMedica shares were down 0.9% to 336.00 pence each on Tuesday morning in London.

Copyright 2023 Alliance News Ltd. All Rights Reserved.